Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2020; 26(39): 6027-6036
Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.6027
Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.6027
Real-world treatment attrition rates in advanced esophagogastric cancer
Erica S Tsang, Howard J Lim, Daniel J Renouf, Janine M Davies, Jonathan M Loree, Sharlene Gill, Department of Medicine, BC Cancer, Vancouver V5Z 4E6, Canada
Erica S Tsang, Howard J Lim, Daniel J Renouf, Janine M Davies, Jonathan M Loree, Sharlene Gill, Division of Medical Oncology, University of British Columbia, Vancouver V5Z 4E6, Canada
Author contributions: Tsang ES and Gill S were responsible for conception and design, collection and assembly of data, and data analysis and interpretation; all authors contributed to manuscript writing and provided final approval of the manuscript.
Institutional review board statement: This study was reviewed and approved by Systemic Therapy - Vancouver (BC Cancer), REB number H19-01865.
Conflict-of-interest statement: All authors have no any conflicts of interest.
Data sharing statement: No additional data.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sharlene Gill, MD, Professor, Department of Medicine, BC Cancer, 600 West 10th Avenue, Vancouver V5Z 4E6, Canada. sgill@bccancer.bc.ca
Received: May 10, 2020
Peer-review started: May 10, 2020
First decision: June 13, 2020
Revised: June 24, 2020
Accepted: September 25, 2020
Article in press: September 25, 2020
Published online: October 21, 2020
Peer-review started: May 10, 2020
First decision: June 13, 2020
Revised: June 24, 2020
Accepted: September 25, 2020
Article in press: September 25, 2020
Published online: October 21, 2020
Core Tip
Core Tip: Despite the availability of later lines of therapy for esophagogastric cancer (EGC), there remains limited real-world data about the treatment attrition rates between lines of therapy. In this population-based analysis, we characterize the use and treatment attrition rates for patients with advanced EGC. Among 245 patients, there was a high level of treatment attrition, with 50% receiving one line of therapy, 34% receiving two lines, and 14% receiving three-lines. Improved survival was associated with better baseline Eastern Cooperative Oncology Group and increased lines of therapy. This real-world analysis demonstrating such steep attrition rates highlights the unmet need for more efficacious early-line treatment options.